SERA

Sera Prognostics, Inc.
CAPPED RATING

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Sera Prognostics, Inc. (SERA) is rated C (2.2/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (B+); its weakest is Value (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.2 / 5.0
C
Value
F
Factor Score 0.0 / 5.0
Growth
B+
Factor Score 3.6 / 5.0
Profitability
D+
Factor Score 1.8 / 5.0
Momentum
B-
Factor Score 3.1 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -3.5
EV / EBITDA -1.1
Rev Growth YoY 162.5%
Gross Margin N/M
Price Return 3M 3.1%
Price Return 12M -35.6%
Catalyst Signal 0.00
Market Cap $79.9M
TTM Revenue $96.0K
Price / Sales 832.7
ROE -49.7%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 F (0.0) B+ (3.6) D+ (1.8) B- (3.1) C+ (2.6) C (2.2)
2026-11-07 F (0.0) B (3.4) D+ (1.8) B- (3.1) C+ (2.7) C (2.2)
2026-10-31 F (0.0) B (3.3) C- (1.9) C+ (2.7) C+ (2.7) C- (2.1)
2026-10-24 F (0.0) B (3.3) C- (1.9) C+ (2.6) C+ (2.6) C- (2.1)
2026-10-17 F (0.0) B (3.3) C- (1.9) C (2.4) C+ (2.6) C- (2.0)
Page 1 of 3